ShareValue scores for 688488.SHG: Valuation 36, Quality 38, Growth 49, Health 42.

688488.SHG
SSE

Jiangsu Aidea Pharmaceutical Co Ltd

CN¥17.54(+8.54%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

-6% to 11%
Valuation
36
Overvalued
Price vs Value
Quality
38
Weak
Business Strength
Growth
49
Moderate
Revenue & Earnings
Health
42
Moderate
Financial Stability
Momentum
45
Neutral
Price Trend

Company Details

About

Jiangsu Aidea Pharmaceutical Group Co., Ltd. develops, produces, and sells pharmaceutical products in China and internationally. It offers anti-HIV drugs and human-derived proteins. The company also provides anti-virus products, such as ainuovirine tablets; urinary protein products, including crude product/intermediate of ulinastatin, urinary kallidinogenase, and urokinase; sennae folium granules; and baicillus cereus tablets. It also exports its products. The company was formerly known as Jiangsu Aidea Pharmaceutical Co., Ltd. and changed its name to Jiangsu Aidea Pharmaceutical Group Co., Ltd. in July 2025. Jiangsu Aidea Pharmaceutical Group Co., Ltd. was founded in 2009 and is headquartered in Yangzhou, China. Address: No. 69, Xinganquan West Road, Yangzhou, China, 225008

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026